Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingUniveraHealthcare PET Oncologic Coverage Update | …
    Ask Trek AI about this page
    CurrentuniverahealthcarePolicy 6.01.29

    Positron Emission Tomography (PET) Oncologic Applications

    Customize your policy alerts

    Sign up for univerahealthcare Policy 6.01.29 alerts

    Get alerted when Policy 6.01.29 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria for FDG PET and PET/CT in oncologic indications across multiple cancer types for Univera Healthcare members and providers.

    Policy Summary
    Payeruniverahealthcare
    PolicyPositron Emission Tomography (PET) Oncologic Applications
    Policy CodePolicy 6.01.29
    Change TypeNo material changes
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionObtain prior authorization when PET/CT is ordered for oncologic indications to document qualifying clinical criteria and timing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    54document length
    Multiplecovered cancer types
    2026-10-15effective date
    Not routinesurveillance (asymptomatic)
    Pre/Post

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CAR‑T scans

    Coverage Criteria — Cancer-specific PET Indications

    General Appropriateness Conditions

    FDG PET or FDG PET/CT is considered medically appropriate when BOTH of the following are met:

    Primary appropriateness conditions: Conventional studies are non-diagnostic; It is used to determine the optimal site for biopsy.

    These general conditions must be met before applying cancer-specific criteria.

    Anal Cancer

    Anal cancer — PET/CT is covered for staging, restaging, and excludes routine surveillance.

    Initial Work-up/Staging: Stage II–III squamous cell carcinoma of the anal canal (not anal margin) with no evidence of metastatic disease on conventional imaging; OR inconclusive findings on conventional imaging.

    Applies to anal canal SCC only.

    Restaging/Recurrence: PET/CT is medically necessary when there are inconclusive findings on conventional imaging.
    Surveillance: PET/CT imaging is not routinely medically necessary for surveillance in an asymptomatic individual with no clinical or laboratory evidence of disease.

    Surveillance explicitly excluded.

    Breast Cancer

    Breast cancer (invasive and pre‑invasive) — criteria for initial staging and restaging.

    Initial Work-up/Staging: FDG PET/CT is medically necessary for any of the following: Stage III N2 disease or higher; T4 disease; inflammatory breast cancer (T4d); inconclusive CT and/or bone scan; or bone pain when NaF PET/CT may be used if CT, MRI, bone scan and FDG PET/CT are inconclusive for bone metastases.

    Includes bone‑directed NaF PET/CT as noted.

    Restaging/Recurrence: 18F‑FDG PET/CT may be used when CT, MRI and/or bone scan are inconclusive; and for treatment response assessment of bone‑only metastases when a prior bone scan has not been performed for serial comparison. 18F‑NaF PET/CT is appropriate when CT, MRI, bone scan and FDG PET/CT findings are inconclusive.

    Also consider 18F‑FES PET/CT to determine ER status when metastatic biopsy is non‑diagnostic or unsafe.

    Breast Cancer — Covered and Not Covered Uses

    Breast cancer — additional modality-specific uses and not-covered statements.

    FDG PET/CT for bone‑only response: 18F‑FDG PET/CT may be used for treatment response assessment for bone‑only metastases when a prior bone scan has not been performed for serial comparison.
    18F‑NaF PET/CT for bone metastases: 18F‑Sodium Fluoride PET/CT is appropriate for individuals with known or suspected bone metastases when CT, MRI, bone scan and FDG PET/CT findings are inconclusive.
    18F‑FES PET/CT for ER status: 18F‑FES PET/CT may be used to determine estrogen‑receptor status of suspected/known metastatic recurrence when biopsy of the metastatic site is non‑diagnostic/inconclusive or biopsy is unsafe/unable to be performed.
    Not medically necessary uses: PET is not medically necessary for systemic restaging after neoadjuvant chemotherapy or after surgery; PET/CT is not routinely medically necessary for surveillance in an asymptomatic individual with no clinical or laboratory evidence of disease; advanced imaging for distant metastases is not medically necessary for asymptomatic individuals with invasive, pre‑invasive or in‑situ breast cancer.

    Cervical Cancer — Initial Staging and Restaging Criteria

    Cervical cancer — indications for initial work‑up/staging and restaging after therapy.

    Initial work‑up/staging indications: PET/CT or PET/MRI is medically necessary for any of: Stage IB1–IB3 (non‑fertility or fertility‑sparing treatment), Stage II–IVA, any size cervical cancer incidentally found in a hysterectomy specimen, small cell neuroendocrine carcinoma of the cervix (NECC), or inconclusive conventional imaging.

    Modality may be PET/CT or PET/MRI as specified.

    Restaging after therapy indications: PET/CT imaging is medically necessary for restaging after therapy for any of the following: 3–6 months post‑completion for Stage IB3; 3–6 months post‑completion for Stage I treated with post‑operative adjuvant radiation or chemoradiation for positive nodes/parametria/margins or local cervical factors; and within 3–6 months post‑completion for Stage II–IV.3–6 months

    Timing windows explicitly listed.

    Cervical Cancer — Restaging/Recurrence

    Cervical cancer — restaging/recurrence indications after prior therapy.

    Post‑therapy restaging — Stage I surgical adjuvant: Three to six months post‑completion of therapy for Stage I treated with post‑operative adjuvant radiation or chemoradiation for positive nodes, positive parametria, positive margins, or local cervical factors.3-6 months
    Post‑therapy restaging — Stage II–IV: Within three to six months of completion of therapy for Stage II–IV disease.within 3-6 months
    Post‑therapy restaging — NECC: After completion of therapy for small cell neuroendocrine carcinoma of the cervix (NECC) treated with primary chemoradiation.post-therapy

    Cervical Cancer — Surveillance

    Cervical cancer — surveillance following completion of therapy.

    Surveillance PET/CT: Once, 3–6 months after completion of therapy.once at 3-6 months

    Surveillance limited to a single post‑therapy study within the specified window.

    Colorectal Cancer — Initial Work-up/Staging

    Colorectal cancer — PET/CT medically necessary for initial work‑up/staging when any listed criterion is met.

    Isolated metastasis for curative intent: Isolated metastatic lesion(s) on other imaging when the patient is a candidate for aggressive surgical resection or other localized treatment (thermal ablation/embolization) with curative intent.

    Documentation should support candidacy for localized curative therapy.

    Inconclusive conventional imaging: Inconclusive findings on conventional imaging.

    PET/CT may be used when CT/MRI are non‑diagnostic.

    Contraindication to IV contrast: When liver‑directed therapies are being considered and the individual has a contraindication to IV contrast.

    PET/CT acceptable as alternative when contrast CT is not possible.

    Colorectal Cancer — Restaging/Recurrence

    Colorectal cancer — restaging/recurrence — PET/CT medically necessary when any listed criterion is met.

    Isolated metastasis for curative intent: Isolated metastatic lesion(s) on other imaging when the patient is a candidate for aggressive surgical resection or other localized treatment to metastasis for curative intent.
    Differentiate recurrence vs scarring: To differentiate local tumor recurrence from postoperative and/or post‑radiation scarring.
    Rising postoperative markers: Postoperative elevated or rising carcinoembryonic antigen (CEA) or liver function tests (LFTs) with negative recent conventional imaging.rising CEA or LFTs

    Document rising markers and prior negative imaging.

    Colorectal Cancer — Surveillance (Not Medically Necessary)

    Colorectal cancer — surveillance stance.

    Surveillance not covered: PET/CT imaging is not medically necessary for surveillance imaging for colorectal cancers.N/A

    Surveillance explicitly listed as not medically necessary.

    Small Bowel Cancer — Initial Work-up/Staging and Restaging

    Small bowel cancer — initial staging not covered; restaging criteria listed.

    Initial staging not covered: PET/CT imaging is not medically necessary for initial staging for small bowel cancer.N/A

    Initial staging explicitly not covered.

    Restaging — rising markers: Postoperative elevated or rising CEA or LFTs with negative recent conventional imaging.rising CEA or LFTs
    Restaging — isolated metastasis: Isolated metastatic lesion(s) on other imaging when the patient is a candidate for aggressive localized therapy (e.g., resection, ablation) for curative intent.

    Small bowel cancer - Initial Staging

    Small bowel cancer — summary statement for initial staging.

    Initial staging small bowel: PET/CT imaging is not medically necessary for initial staging for small bowel cancer.

    Colorectal/Small Bowel - Restaging/Recurrence

    Colorectal and small bowel — combined restaging/recurrence indications.

    Restaging/Recurrence indications: Postoperative elevated or rising CEA or LFTs with negative recent conventional imaging; OR isolated metastatic lesion(s) on other imaging when the patient is a candidate for aggressive surgical resection or other localized treatment to metastasis for curative intent.

    Either indication justifies PET/CT for restaging/recurrence.

    Esophageal/GE junction - Initial and Restaging

    Esophageal / GE‑junction cancer — initial staging and restaging with specified timing after radiation.

    Initial work‑up/staging: PET/CT imaging is medically necessary for initial work‑up/staging if there is no evidence of metastatic disease by conventional imaging.
    Restaging — inconclusive imaging: PET/CT imaging is medically necessary for restaging when conventional imaging is inconclusive.
    Post‑therapy timing: When restaging after completion of chemoradiation or primary therapy prior to surgery, PET/CT should be performed no sooner than five (5) weeks after completion of radiation therapy.>=5 weeks

    Timing requirement explicitly stated.

    Salvage surgical candidate: For a salvage surgical candidate with recurrence and no metastatic disease documented by conventional imaging.

    Surveillance - Not routinely necessary

    Surveillance — general exclusion for asymptomatic individuals.

    Surveillance exclusion: PET/CT imaging is not routinely medically necessary for surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease (applies across multiple tumor types).

    Used for colorectal, small bowel, esophageal/GE junction and other cancers as specified.

    CLL/SLL - Evaluation and Suspected Transformation

    CLL/SLL — PET/CT generally not indicated except for suspected Richter's transformation.

    General CLL/SLL evaluation: PET imaging is not medically necessary in the routine evaluation of CLL/SLL, except when there is clinical suspicion for Richter's transformation.

    Routine PET not indicated for CLL/SLL.

    Suspected Richter's transformation: PET/CT is medically necessary for suspected transformation when any of the following are present: new B symptoms; rapidly growing lymph nodes; development of extranodal disease; or a significant recent rise in LDH above the normal range.

    Clinical triggers for transformation are enumerated.

    NSCLC Suspected/Diagnosis

    NSCLC — suspected/diagnosis: nodule size criterion.

    NSCLC suspected/diagnosis: Pulmonary nodule 8 mm to 30 mm seen on CT or MRI chest (if PET is positive it qualifies as initial staging PET/CT).8–30 mm

    Size range for consideration of PET/CT in suspected NSCLC.

    NSCLC Pre‑biopsy

    NSCLC — pre‑biopsy PET/CT considerations for large pulmonary masses.

    Pre‑biopsy PET/CT indication: For a pulmonary mass ≥31 mm, PET/CT prior to biopsy is appropriate if definitive treatment (resection or radiation) would be used instead of biopsy if PET confirms limited disease.>=31 mm

    Also appropriate when multiple biopsy options exist and PET will guide selection of the optimal biopsy site.

    Pre‑biopsy PET/CT indication: When multiple possible biopsy options are present within the chest and PET findings will be used to determine the most favorable biopsy site.>=31 mm

    NSCLC Initial Work‑up/Staging

    NSCLC — initial work‑up/staging after tissue diagnosis.

    Initial staging after diagnosis: PET/CT imaging is medically necessary for initial work‑up/staging for all individuals after histological diagnosis (if not already completed prior to diagnosis).

    Standard requirement for staging in NSCLC.

    NSCLC Restaging/Recurrence

    NSCLC — restaging/recurrence indications where PET/CT is medically necessary.

    Localized chest recurrence: Suspected or biopsy‑proven recurrence localized to the chest cavity.
    Inconclusive conventional imaging: Inconclusive findings on conventional imaging.
    Differentiate tumor vs fibrosis: To differentiate tumor from radiation scar/fibrosis.
    Oligometastatic disease planning: Stage IV disease with oligometastatic lesions on conventional imaging when the patient is a candidate for aggressive surgical resection or other localized treatment of metastases with curative intent.

    SCLC Suspected/Diagnosis

    SCLC — suspected/diagnosis nodule size criterion (similar to NSCLC).

    SCLC suspected/diagnosis: Pulmonary nodule 8 mm to 30 mm seen on CT or MRI chest (if PET positive qualifies as initial staging PET/CT).8–30 mm

    Size range criterion applies to suspected SCLC lesions.

    SCLC Pre‑biopsy

    SCLC — pre‑biopsy PET/CT when mass ≥31 mm and PET will affect management.

    SCLC pre‑biopsy indication: For a pulmonary mass ≥31 mm, PET/CT is appropriate prior to biopsy if definitive treatment with resection or radiation would be used instead of biopsy if PET confirms limited disease.>=31 mm

    Also appropriate when multiple biopsy options exist and PET will guide biopsy site selection.

    SCLC Initial Work‑up/Staging

    SCLC — initial work‑up/staging indications.

    Confirm limited disease: To confirm the extent of disease when CT chest/abdomen/pelvis and MRI brain indicate limited stage disease (disease confined to one side of the chest).
    Evaluate inconclusive imaging: To evaluate inconclusive findings on conventional imaging.

    SCLC Initial Work-up/Staging

    SCLC — summary initial staging criteria.

    SCLC initial staging: To confirm extent when conventional imaging indicates limited disease; OR to evaluate inconclusive findings on conventional imaging.

    SCLC Restaging/Recurrence

    SCLC — restaging/recurrence stance.

    SCLC restaging: PET imaging is not medically necessary for evaluation of treatment response or recurrence of SCLC in general but can be considered on a case‑by‑case basis.

    Case‑by‑case exceptions possible.

    SCLC Surveillance

    SCLC — surveillance stance.

    SCLC surveillance: PET/CT imaging is not routinely medically necessary for surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease.

    Surveillance explicitly not routine.

    Hodgkin Lymphoma - Indications

    Hodgkin lymphoma — indications for initial staging, timing, response assessment, and CAR‑T monitoring.

    Initial staging/diagnosis: PET/CT may be used as the initial imaging technique for staging/diagnosis.

    Includes classical and nodular lymphocyte predominant subtypes.

    Pre‑therapy repeat PET: Prior to initiation of therapy if one (1) month or more has passed since the previous PET/CT.>=1 month
    Treatment response assessment as frequently as every two (2) cycles when clinically indicated.as frequently as every 2 cycles
    End of therapy imaging: At the end of chemotherapy and again at the end of radiation therapy (at least 12 weeks after completion of radiation).

    Predominant Hodgkin Lymphoma / Low-grade lymphoma transformation monitoring

    Predominant Hodgkin / low‑grade lymphoma transformation monitoring and restrictions.

    Suspected transformation indications: Suspected transformation from a low‑grade lymphoma to a more aggressive type based on development of extranodal disease or a significant recent rise in LDH above the normal range.
    Post‑therapy Deauville follow‑up: A single follow‑up PET/CT may be approved at 3 months if the end‑of‑therapy PET/CT shows Deauville 4 or 5 FDG avidity.3 months
    CAR‑T schedule: PET/CT once before CAR‑T treatment and once 30–60 days after completion of treatment.30-60 days
    Pre‑histologic confirmation restriction:

    Melanoma — initial staging, restaging, surveillance

    Melanoma — initial staging and restaging indications, and surveillance stance.

    Initial staging indications: PET/CT is medically necessary for initial staging for Stage III (sentinel node positive and palpable regional nodes), Stage IV (metastatic), or when the primary site is unknown and CT chest/abdomen/pelvis are negative.
    Restaging indications: PET/CT is medically necessary for restaging/recurrence when conventional imaging is inconclusive or when an isolated metastatic site is found on conventional imaging.
    Surveillance stance: PET/CT imaging is not routinely medically necessary for surveillance in an asymptomatic individual with no clinical or laboratory evidence of disease.

    Non-melanoma skin cancer (including Merkel cell carcinoma)

    Non‑melanoma skin cancer — Merkel cell carcinoma and dermal metastasis evaluation.

    Initial work‑up indications: PET/CT is medically necessary for skin lesions that may represent dermal metastasis from a distant primary when CT or MRI cannot identify the primary, and for Merkel cell carcinoma initial work‑up/staging.
    Restaging/recurrence — Merkel cell carcinoma: PET/CT is medically necessary for Merkel cell carcinoma when conventional imaging is inconclusive; or if no conventional imaging has been performed and there is biopsy‑proven recurrence or suspected in‑transit metastatic disease from an extremity primary.

    Merkel cell carcinoma — Restaging/Recurrence

    Merkel cell carcinoma — restaging/recurrence specifics.

    Inconclusive conventional imaging: PET/CT is medically necessary when conventional imaging is inconclusive.
    Biopsy‑proven recurrence without prior imaging: If no conventional imaging has been performed, PET/CT is medically necessary for biopsy‑proven recurrence of Merkel cell carcinoma.
    Suspected in‑transit metastatic disease: If no conventional imaging has been performed and suspected in‑transit metastatic disease from an extremity primary exists, PET/CT is medically necessary.

    Bone metastasis evaluation

    Bone metastasis evaluation — FDG PET/CT medically necessary when at least one listed condition applies.

    Bone lesion on x‑ray (age criterion): Individual ≥ 40 years with a bone lesion seen on x‑ray.age >= 40

    Age threshold specified.

    Symptomatic bone lesion without prior malignancy: Individual ≥ 40 years with no history of malignancy who has a symptomatic bone lesion seen on x‑ray and malignancy is suspected.age >= 40
    Inconclusive bone imaging: FDG PET/CT when bone metastases are suspected and both bone scan and either CT or MRI are inconclusive.

    Use when other bone imaging is non‑diagnostic.

    Brain metastasis evaluation

    Brain metastasis evaluation — PET/CT (or PET metabolic brain) indications.

    Inconclusive conventional brain imaging: PET/CT is medically necessary when conventional brain imaging is inconclusive for metastases.
    Brain metastases with no known primary tumor.
    Confirm systemic disease status: To confirm either stable systemic disease or absence of other metastatic disease.
    Differentiate necrosis versus progression post‑radiation: When recent MRI brain and MR perfusion are both unable to distinguish radiation necrosis versus tumor progression, PET metabolic brain is appropriate.

    Adrenal and Liver metastasis evaluation

    Adrenal and liver metastasis evaluation — selected indications for PET/CT.

    Adrenal — non‑diagnostic biopsy: Adrenal lesion where biopsy is not feasible or is non‑diagnostic.
    Adrenal — isolated metastasis: Adrenal isolated metastasis on conventional imaging when the patient is a candidate for aggressive surgical management.
    Liver — confirm solitary metastasis: To confirm a solitary liver metastasis amenable to resection on conventional imaging.
    Liver — rising LFTs/tumor markers: When LFTs and/or tumor markers continue to rise and CT and MRI are negative.

    Liver - covered indications

    Liver — covered indications summarized.

    Confirm solitary resectable metastasis: To confirm solitary metastasis amenable to resection on conventional imaging.
    Rising markers with negative CT/MRI: When liver function tests and/or tumor markers continue to rise and CT and MRI are negative.

    Liver - not medically necessary

    Liver — not medically necessary uses.

    Assessing response to ablation: Assessing the response to ablation therapy (regardless of ablation modality) is not medically necessary.
    Routine surveillance: PET imaging is not medically necessary for routine surveillance of asymptomatic individuals after treatment completion.

    Lung - covered indications

    Lung — covered indications including nodule threshold.

    Lung nodule threshold: Lung nodules greater than or equal to 8 mm.>= 8 mm

    Nodule size threshold specified.

    Confirm solitary metastasis: To confirm a solitary metastasis amenable to resection on conventional imaging.

    Occult Primary - covered indications

    Occult primary — PET/CT covered when prior evaluations cannot identify the primary or when isolated metastasis with curative intent is planned.

    Occult primary — prior negative imaging: Primary cancer site cannot be determined by prior CT, MRI, bone scan or diagnostic mammogram and full pelvic exam.

    Document prior imaging and exam.

    Occult primary — isolated metastatic disease: CT imaging reveals isolated metastatic disease for which definitive curative therapy is planned.

    Multiple Myeloma and Plasmacytomas - Initial Work-up/Staging

    Multiple myeloma and plasmacytomas — whole‑body FDG PET/CT initial work‑up/staging indications.

    POEMS / sclerotic lesions: Suspected or known POEMS syndrome for sclerotic bone lesions on other imaging.
    Systemic light chain amyloidosis: Suspected or known systemic light chain amyloidosis.
    Confirmed myeloma: Confirmed multiple myeloma.
    Abnormal skeletal survey or imaging: Myeloma suspected based on abnormal skeletal survey or other imaging.
    Abnormal myeloma labs: Myeloma suspected based on abnormal myeloma labs.

    Multiple Myeloma and Plasmacytomas - Restaging/Recurrence

    Multiple myeloma/plasmacytomas — restaging/recurrence and CAR‑T considerations.

    CAR‑T timing: CAR‑T cell therapy: once before treatment and once 30–60 days after completion of treatment.30-60 days

    Peri‑CAR‑T imaging schedule.

    Management change indication: When a negative PET will allow change in management from active treatment to maintenance or surveillance.

    Restaging/Recurrence

    Multiple myeloma/plasmacytomas — restaging/recurrence: broader indications.

    Restaging/Recurrence indications: CAR‑T pre/post imaging; when a negative PET will permit change to maintenance/surveillance; inconclusive conventional imaging; when whole‑body low‑dose skeletal CT is unavailable or impractical and recurrence/progression is suspected; suspected progression or relapse; suspected progression of MGUS or SMM to a more malignant form.

    Multiple distinct restaging triggers are enumerated.

    Repeat Imaging / Treatment Response Assessment

    Repeat whole‑body FDG PET/CT — treatment response and repeat imaging conditions.

    Baseline requirement: PET/CT was used for initial diagnosis.

    Repeat PET/CT is allowed only when baseline PET/CT exists.

    Treatment response assessment indications: After completion of primary therapy; for non‑secretory multiple myeloma; to determine therapy response when labs are inconclusive; or for extra‑osseous plasmacytoma response to initial therapy.

    At least one of these indications must be met in addition to the baseline requirement.

    Stem Cell Transplant

    Stem cell transplant — peri‑transplant PET/CT schedule.

    Stem cell transplant imaging: PET/CT is medically necessary once before transplant and once within 30–100 days after transplant for stem cell transplant recipients.30-100 days

    Peri‑transplant timing window specified.

    Surveillance

    Surveillance — when whole‑body FDG PET/CT may be used for myeloma and plasmacytoma follow‑up.

    Smoldering myeloma surveillance: Smoldering myeloma — annual whole‑body FDG PET/CT if the same modality was used at diagnosis.annual
    Multiple myeloma surveillance: Multiple myeloma — annual whole‑body FDG PET/CT if the same modality was used at diagnosis.annual
    Solitary plasmacytoma surveillance: Solitary plasmacytomas — annual whole‑body FDG PET/CT for 5 years if same modality used at diagnosis.annual for 5 years

    Adrenal Tumors Initial Staging

    Adrenal tumors — initial work‑up/staging for individuals with hypercortisolemia.

    Tumor size: Tumor greater than 4 cm.

    Size criterion for FDG PET/CT in hypercortisolemia.

    Morphology: Inhomogeneous tumor appearance.

    Other malignant imaging features addressed in companion node.

    Initial staging for hypercortisolemia

    Initial staging for hypercortisolemia — FDG PET/CT is medically necessary when any listed imaging characteristic is present.

    Hypercoritsolemia imaging features: Tumor > 4 cm; Inhomogeneous; Irregular margins; Local invasion; OR other malignant imaging characteristics.

    Any one of these imaging features in the setting of hypercortisolemia justifies FDG PET/CT.

    Initial work-up/staging after negative/inconclusive conventional imaging

    Initial work‑up/staging after negative or inconclusive conventional imaging — SSR PET/CT or FDG PET/CT options.

    Continued suspicion after CT/MRI: When continued clinical suspicion persists with negative or inconclusive CT or MRI, PET/CT or PET/MRI using an SSR radiotracer (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) is medically necessary; FDG PET/CT is an alternative when CT, MRI, Octreotide, MIBG, or SPECT are negative or inconclusive.

    Specifies SSR agents and FDG alternative pathway.

    Restaging/recurrence and PRRT assessment

    Restaging/recurrence and PRRT assessment — neuroendocrine tumors and selected FDG uses.

    SSR restaging/recurrence: PET/CT or PET/MRI with SSR radiotracers (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) is medically necessary for restaging/recurrence when continued suspicion exists and CT/MRI are negative or inconclusive.
    PRRT candidacy assessment: PET/CT imaging is medically necessary to assess candidacy for peptide receptor radionuclide therapy (Lutetium‑177 Lu‑dotatate).

    Explicit PRRT assessment indication.

    FDG restaging indications: FDG PET/CT is medically necessary for restaging/recurrence if prior CT/MRI/Octreotide/MIBG/SPECT are negative or inconclusive; for hypercortisolemia with inconclusive CT; and for pheochromocytoma/paraganglioma with bone‑dominant disease.

    FDG role defined when SSR or other imaging negative/inconclusive.

    Adrenocortical carcinoma — FDG PET/CT

    Adrenocortical carcinoma — FDG PET/CT indications.

    Adrenocortical carcinoma indications: FDG PET/CT is medically necessary for initial staging; and for suspected recurrence when conventional imaging is inconclusive.

    FDG PET/CT for restaging/recurrence

    FDG PET/CT — restaging/recurrence for adrenal/pheochromocytoma/paraganglioma scenarios.

    Pheochromocytoma/paraganglioma restaging: FDG PET/CT is medically necessary for restaging/recurrence in settings such as hypercortisolemia with inconclusive CT, pheochromocytoma bone‑dominant disease, or paraganglioma bone‑dominant disease.

    Initial work-up/staging and restaging/recurrence

    Bronchopulmonary / thymic carcinoids — SSR PET for initial work‑up and restaging; FDG role when SSR or other studies are negative.

    Initial work‑up/staging — SSR PET: PET/CT or PET/MRI with SSR radiotracers (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) is medically necessary when CT/MRI are inconclusive, or for locally advanced/metastatic disease not amenable to curative resection to assess candidacy for somatostatin analogue therapy.

    SSR agents listed explicitly.

    FDG PET indications: FDG PET/CT or PET/MRI is medically necessary when markers fail to normalize after complete surgical resection and CT/MRI and somatostatin‑receptor study are negative; or for biopsy‑proven NET of unknown primary when CT/MRI and somatostatin‑receptor study are negative.
    Restaging/recurrence — SSR PET: PET/CT or PET/MRI with SSR radiotracers is medically necessary for restaging/recurrence when there is continued suspicion and CT/MRI are negative or inconclusive.

    Bronchopulmonary/Thymic Carcinoids - Restaging/Recurrence

    Bronchopulmonary/thymic carcinoids — restaging/recurrence SSR agents.

    Allowed SSR agents: 68Ga‑DOTATATE OR 68Ga‑DOTATOC OR 64Cu‑DOTATATE may be used for restaging/recurrence.

    Specific SSR radiotracers enumerated.

    Bronchopulmonary/Thymic Carcinoids - Surveillance (Not Routine)

    Bronchopulmonary/thymic carcinoids — surveillance stance.

    Surveillance not routine: PET/CT is not routinely medically necessary for surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease.

    Surveillance explicitly not routinely covered.

    Gastrointestinal/Pancreatic Neuroendocrine Cancer - Initial Work-up/Staging

    Gastrointestinal / pancreatic neuroendocrine cancer — SSR PET/CT indications for initial work‑up/staging.

    Anatomic/histologic indications: Well‑differentiated grade 1–2 tumors of jejunal, ileal, colon, gastric type 3, neuroendocrine tumors of unknown primary; well‑differentiated Grade 3 tumors; locally advanced or metastatic disease not amenable to curative resection to assess candidacy for somatostatin analogues.

    Anatomic and histologic groups listed.

    Imaging modality and tracers: PET/CT or PET/MRI with SSR radiotracers (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) when CT/MRI are inconclusive.

    SSR tracers enumerated.

    Gastrointestinal/Pancreatic Neuroendocrine Cancer - FDG PET/CT

    Gastrointestinal / pancreatic NET — FDG PET/CT indications.

    FDG PET indications: FDG PET/CT is medically necessary when markers fail to normalize after complete surgical resection and CT/MRI and somatostatin‑receptor based study are negative; OR when there is biopsy‑proven NET of unknown primary and CT/MRI and somatostatin‑receptor study are negative.

    FDG used when SSR and other imaging modalities are negative.

    Gastrointestinal/Pancreatic Neuroendocrine Cancer - Suspected/Diagnosis

    GI / pancreatic NET — suspected/diagnosis pathway using SSR PET when CT/MRI are inconclusive.

    Suspected/diagnosis — continued suspicion: PET/CT or PET/MRI with an SSR radiotracer (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) is medically necessary when there is continued clinical suspicion after negative or inconclusive CT or MRI.

    SSR agents enumerated in companion nodes.

    Initial suspected/diagnosis for GI/pancreatic neuroendocrine cancer

    GI / pancreatic NET — suspected/diagnosis covered when ALL of the listed conditions are met.

    Neuroendocrine suspected/diagnosis: Continued suspicion for GI/pancreatic neuroendocrine tumor after negative or inconclusive CT or MRI AND use of one of the SSR radiotracers (68Ga‑DOTATATE; 68Ga‑DOTATOC; 64Cu‑DOTATATE).

    Both continued suspicion and SSR tracer requirement must be met.

    Restaging/recurrence for GI/pancreatic neuroendocrine cancer

    GI / pancreatic NET — restaging/recurrence and PRRT candidacy assessment.

    Suspected recurrence: PET/CT or PET/MRI is medically necessary for suspected recurrence.
    PRRT candidacy assessment: To assess candidacy for peptide receptor radionuclide therapy (Lutetium‑177 Lu‑dotatate).

    Explicit PRRT indication.

    Allowed SSR radiotracer: Use of one of the SSR radiotracers: 68Ga‑DOTATATE; 68Ga‑DOTATOC; 64Cu‑DOTATATE.

    Surveillance

    Surveillance — general not‑medically‑necessary statement.

    Surveillance exclusion: PET/CT imaging is not medically necessary for surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease.

    Applies broadly across tumor types as specified in policy.

    Non-Hodgkin Lymphomas general criteria

    Non‑Hodgkin lymphomas — general criteria: biopsy planning and CAR‑T timing.

    Biopsy site selection: To determine a more favorable site for biopsy when a relatively inaccessible site is contemplated.

    Used to guide optimal biopsy selection.

    CAR‑T timing: For CAR‑T cell therapy: once before treatment and once 30–60 days after completion of treatment.30-60 days

    PET/CT indicated for peri‑CAR‑T monitoring.

    DLBCL initial and restaging criteria

    DLBCL — initial staging and treatment‑timed restaging criteria.

    Initial staging: PET/CT may be used as the initial imaging technique for staging/diagnosis of DLBCL and related aggressive subtypes.

    Includes grey‑zone, primary mediastinal B‑cell and other specified subtypes.

    Treatment response — stage I–II: Treatment response assessment after 3–4 cycles of chemotherapy for stage I and II without extensive mesenteric disease (in lieu of CT or if CT is inconclusive).after 3-4 cycles

    Timing specified for interim response.

    Treatment response — stage II–IV: Treatment response assessment after 2–4 cycles for stage II with extensive mesenteric disease and stages III–IV (in lieu of CT or if CT is inconclusive).after 2-4 cycles

    DLBCL Restaging/Recurrence

    DLBCL — restaging/recurrence, end‑of‑therapy, and CAR‑T monitoring.

    DLBCL restaging/recurrence: Treatment response assessment per specified chemotherapy cycles; end of chemotherapy and/or end of radiation therapy imaging; suspected recurrence including rare circumstances (e.g., bone involvement); biopsy‑confirmed recurrence; and CAR‑T cell therapy monitoring (once before and once 30–60 days after completion).

    Multiple restaging and monitoring triggers detailed.

    Follicular Lymphoma Criteria

    Follicular lymphoma — initial staging and restaging/recurrence indications.

    Initial staging — radiation planning: Initial work‑up/staging when radiation therapy is being considered for Stage I or II disease; or when CT results lead to a plan for systemic therapy.
    Restaging / suspected transformation: End of therapy evaluation; or suspected transformation to a more aggressive type based on new B symptoms, rapidly growing nodes, development of extranodal disease, or a significant recent rise in LDH above normal range.

    Surveillance PET/CT is generally limited. Per policy language, PET/CT imaging is not routinely medically necessary for surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease. This surveillance exclusion applies across multiple cancer types and is a common denial trigger when no clinical or laboratory concern is documented.

    Top-level Covered Indications (by disease site)

    Prior Authorization, Documentation, and Operational Notes

    Prior Authorization

    Prior authorization required for PET/CT oncology requests

    Prior authorization is implied for FDG PET/CT used in oncologic indications and coverage is contingent on meeting the policy’s cancer‑specific criteria (i.e., conventional studies non‑diagnostic and use to determine an optimal biopsy site).

    Prior Authorization

    Authorize PET/CT or PET/MRI for cervical cancer staging/restaging

    PET/CT or PET/MRI for cervical cancer initial staging or restaging requires prior authorization and must meet the listed stage‑specific criteria (e.g., Stage IB1–IB3, Stage II–IVA) or specified post‑therapy timing.

    Prior Authorization

    Authorization expected for listed PET/CT indications

    Prior authorization is expected when PET/CT is ordered for the policy’s listed indications (initial staging, restaging, surveillance) to document the qualifying clinical scenario such as inconclusive conventional imaging, isolated metastasis amenable to local therapy, or rising tumor markers.

    Applicable Procedures, Codes, and Key Parameters

    Applicable procedures (descriptive)mixed
    Not specifiedDocument section lists FDG PET/CT indications but does not enumerate CPT/HCPCS codes in these chunks.
    Covered SSR radiotracersmixedCovered
    68Ga-DOTATATESSR radiotracer 68 Gallium DOTATATE
    68Ga-DOTATOCSSR radiotracer 68 Ga-DOTATOC
    64Cu-DOTATATESSR radiotracer 64 Cu-DOTATATE
    Covered FDG PET/CT indicationsmixedCovered
    FDG PET/CTFluorodeoxyglucose PET/CT imaging
    SSR Radiotracersmixed
    68 Gallium DOTATATESSR PET radiotracer listed for multiple indications
    68 Ga-DOTATOCSSR PET radiotracer listed for multiple indications
    64 Cu-DOTATATESSR PET radiotracer listed for multiple indications
    FDG PET/CTmixed
    FDG PET/CTFluorodeoxyglucose PET/CT imaging for NETs when SSR studies or CT/MRI are negative or markers fail to normalize
    inv-99: Pulmonary nodule size
    Pulmonary nodule size8 mm to 30 mm
    ContextApplies to pulmonary nodules seen on CT or MRI chest where a positive PET converts the exam to initial staging PET/CT
    Related guidanceSame size range cited for SCLC suspected/diagnosis
    inv-100: Pulmonary mass threshold
    Pulmonary mass threshold≥ 31 mm (3.1 cm)
    Pre-biopsy usePET/CT may be appropriate prior to biopsy for masses ≥31 mm if PET findings will change management (definitive resection/radiation instead of biopsy) or select optimal biopsy site

    Timing and Frequency Constraints

    inv-228: PET/CT — As frequently as every 2 cycles
    Frequency limitAs frequently as every 2 cycles
    Applies toTreatment response assessment in Hodgkin lymphoma
    Use caseInterim PET/CT during chemotherapy cycles to assess response
    inv-229: PET/CT — Single follow-up at 3 months
    Single follow-up timingSingle follow-up PET/CT may be approved at 3 months
    TriggerEnd-of-therapy PET/CT shows Deauville score of 4 or 5
    Applies to

    Prior Authorization Expectations

    Prior Authorization

    Implied requirement: meet listed criteria before FDG PET/CT coverage

    FDG PET/CT coverage is contingent on meeting the policy’s general and cancer‑specific criteria (conventional studies non‑diagnostic and used to determine an optimal biopsy site); prior authorization should confirm criteria are met.

    Prior Authorization

    Specify PET/CT or PET/MRI and 3–6 month timing for cervical cancer

    PET/CT or PET/MRI is the authorized modality for initial cervical cancer staging and for restaging/surveillance once at 3–6 months post‑therapy for specified stages — prior authorization should specify modality and timing.

    Prior Authorization

    Require documentation for non‑routine PET/CT indications

    Prior authorization is required when PET/CT is requested for indications outside routine use or when documentation of qualifying criteria (isolated metastasis for curative intent, rising markers, inconclusive conventional imaging) is needed.

    Contrast and Alternative Imaging Considerations

    Billing Rule

    Accept PET/CT when IV contrast is contraindicated for liver therapy planning

    PET/CT is acceptable for initial work‑up/staging when IV contrast is contraindicated and liver‑directed therapies are being considered — document the contrast contraindication on the authorization to support medical necessity.

    Billing Rule

    Justify PET/CT if low‑dose skeletal CT is available

    When whole‑body low‑dose skeletal CT is available and practical, PET/CT may not be considered necessary; authorization requests should explain why CT is unavailable or impractical if PET/CT is being requested instead.

    Not Medically Necessary / Exclusions

    PET/CT should not be used to evaluate lymphoma before tissue diagnosis. The policy explicitly states that PET/CT is not medically necessary for indications prior to histological confirmation of lymphoma, and routine surveillance PET/CT in asymptomatic individuals without clinical or laboratory evidence of disease is also not routinely medically necessary.

    PET imaging of the liver has specific limits: it is not medically necessary to assess response to ablation therapy regardless of ablation modality, and it is also not medically necessary for routine surveillance of asymptomatic individuals after treatment completion.

    For bronchopulmonary and thymic carcinoid, PET/CT with somatostatin-receptor radiotracers is allowed for restaging when conventional imaging is inconclusive, but the policy specifies that PET/CT surveillance imaging is not routinely medically necessary for asymptomatic individuals with no clinical or laboratory evidence of disease.

    Routine surveillance PET/CT in asymptomatic individuals without clinical or laboratory evidence of disease is uniformly discouraged. The policy repeats that surveillance imaging in such patients is not routinely medically necessary and may be denied when no qualifying clinical or laboratory rationale is documented.

    Policy-level summaries of surveillance and other exclusions: PET/CT is not medically necessary prior to histological confirmation of lymphoma, PET liver imaging is not medically necessary to assess ablation response or for routine surveillance, and PET/CT surveillance for asymptomatic individuals with no clinical or laboratory evidence of disease (including carcinoid and other listed tumors) is not routinely medically necessary.

    Background and Definitions

    Background: FDG PET and FDG PET/CT are intended as problem-solving tools in oncology. The policy frames these modalities as appropriate when there is a high likelihood of cancer and when conventional imaging is non-diagnostic or when PET/CT will determine an optimal biopsy site. Importantly, routine surveillance of asymptomatic individuals without clinical or laboratory evidence of disease is explicitly not supported and is identified throughout the document as not medically necessary.

    inv-168: FDG PET/CT definition
    DefinitionFluorodeoxyglucose (FDG) positron emission tomography integrated with computed tomography
    UseOncologic evaluation when conventional studies are non-diagnostic and to determine optimal biopsy site
    Modality nameReferred to in policy as FDG PET/CT or FDG PET
    inv-169: 18F-FES PET/CT definition
    Definition

    Policy Revision History

    2026-10-15Policy effective dateLatest

    Policy 6.01.29 became effective, establishing surveillance frequency: annual whole-body FDG PET/CT for smoldering myeloma and multiple myeloma, and annual surveillance for solitary plasmacytomas for 5 years.

    Policy Summary
    Payeruniverahealthcare
    PolicyPositron Emission Tomography (PET) Oncologic Applications
    Policy CodePolicy 6.01.29
    Change TypeNo material changes
    Effective DateOct 15, 2026
    Last ReviewJun 18, 2026
    Next Review DateJun 1, 2027
    Key ActionObtain prior authorization when PET/CT is ordered for oncologic indications to document qualifying clinical criteria and timing.
    SourceLink
    On This Page
    Coverage Criteria — Cancer-specific PET IndicationsTop-level Covered Indications (by disease site)Prior Authorization, Documentation, and Operational NotesApplicable Procedures, Codes, and Key ParametersTiming and Frequency ConstraintsPrior Authorization ExpectationsContrast and Alternative Imaging ConsiderationsNot Medically Necessary / ExclusionsBackground and DefinitionsPolicy Revision History

    Surveillance and advanced asymptomatic screening explicitly not covered.

    Restaging — imaging or recurrence: When conventional imaging is inconclusive; or for suspected or biopsy‑proven recurrence.N/A
    >=12 weeks post radiation
    Suspected recurrence ≥3 months after completion of therapy.>=3 months
    Follow‑up for Deauville 4–5: A single follow‑up PET/CT may be approved at 3 months if the end‑of‑therapy PET/CT shows Deauville 4 or 5 FDG avidity.3 months
    CAR‑T therapy timing: Once before CAR‑T treatment and once 30–60 days after completion of treatment.30-60 days

    Peri‑CAR‑T imaging schedule.

    Biopsy‑proven recurrence is an indication for PET/CT in appropriate contexts.
    Suspected transformation criteria: Suspected transformation from low‑grade lymphoma to a more aggressive type based on new B symptoms; rapidly growing nodes; development of extranodal disease; or a significant recent rise in LDH above the normal range.

    Clinical triggers listed.

    PET/CT is not medically necessary for indications prior to histological confirmation of lymphoma.

    Requests prior to tissue diagnosis may be denied.

    Signs/symptoms of myeloma: Myeloma suspected based on signs or symptoms of multiple myeloma.
    Inconclusive low‑dose skeletal CT: PET/CT when there are inconclusive findings on whole‑body low‑dose skeletal CT.
    Prior Authorization

    Observe ≥5‑week post‑radiation interval before restaging PET/CT

    For esophageal/GE junction cancer restaging after chemoradiation, PET/CT should not be performed sooner than five weeks after completion of radiation therapy — prior authorization should reflect this timing.

    Prior Authorization

    Authorize PET/CT for initial staging after diagnosis or to confirm limited SCLC

    Prior authorization is implied for PET/CT used for initial work‑up/staging after tissue diagnosis or to confirm extent of limited SCLC when conventional imaging indicates limited disease.

    Prior Authorization

    Single 3‑month follow‑up allowed if Deauville 4–5

    A single follow‑up PET/CT at three months may be approved when the end‑of‑therapy PET/CT demonstrates Deauville score 4 or 5 FDG avidity; prior authorization should note this limited approval.

    Prior Authorization

    Authorize CAR‑T baseline and 30–60 day PET/CT with timing documented

    Prior authorization is implied for PET/CT when used for CAR‑T therapy (one baseline and one 30–60 day post‑treatment scan); authorization should document intent for baseline and post‑treatment timing and note that single 3‑month follow‑up approvals (Deauville 4–5) are separate.

    Prior Authorization

    Require authorization for Merkel cell or specified metastatic indications

    Prior authorization is required when PET/CT is requested for Merkel cell carcinoma restaging/recurrence or for specified metastatic disease evaluations (e.g., adrenal) and when conventional imaging is inconclusive or biopsy is not feasible.

    Prior Authorization

    Prior authorization may be required to document CAR‑T PET timing

    When PET is requested for CAR‑T therapy scheduling, prior authorization may be required to document intent for one scan before treatment and one scan 30–60 days after completion.

    Prior Authorization

    Timing‑based authorization for CAR‑T and stem cell transplant imaging

    Prior authorization requests should reflect planned timing for PET/CT around CAR‑T (once before and once 30–60 days after) and for stem cell transplant (once before and once within 30–100 days after transplant).

    Prior Authorization

    Authorize PET/CT for PRRT candidacy assessment

    Prior authorization is required when PET/CT is performed to assess candidacy for peptide receptor radionuclide therapy (PRRT) with Lutetium‑177 Lu‑dotatate.

    Prior Authorization

    Authorize SSR PET for carcinoid restaging when CT/MRI inconclusive

    PET/CT or PET/MRI using somatostatin‑receptor radiotracers (e.g., 68Ga‑DOTATATE, 68Ga‑DOTATOC) for restaging/recurrence of carcinoid requires prior authorization when CT/MRI are negative or inconclusive and continued suspicion exists.

    Prior Authorization

    Document SSR radiotracer use on authorization requests

    Prior authorization requests should explicitly reference use of SSR radiotracers (68Ga‑DOTATATE, 68Ga‑DOTATOC, 64Cu‑DOTATATE) when PET/CT or PET/MRI is ordered for initial work‑up/staging of well‑differentiated GI/pancreatic NETs or when CT/MRI is inconclusive.

    Prior Authorization

    Require authorization for PRRT assessment with SSR PET

    Prior authorization is required when PET/CT or PET/MRI is requested to assess candidacy for PRRT or for restaging/recurrence using listed SSR radiotracers.

    Prior Authorization

    Authorize DLBCL PET/CT and document CAR‑T pre/post scans

    For DLBCL, PET/CT is medically necessary for restaging/recurrence; for CAR‑T cell therapy there should be one PET/CT before treatment and one 30–60 days after completion — prior authorization should document these scans.

    Step Therapy

    Step‑up to NaF PET/CT for bone evaluation only after other modalities inconclusive

    18F‑NaF PET/CT may be obtained for bone metastasis evaluation in breast cancer when CT, MRI, bone scan and FDG PET/CT are inconclusive; note this stepwise requirement on the authorization.

    Billing Rule

    Use PET/CT when IV contrast is contraindicated for liver‑directed planning

    When IV contrast is contraindicated and liver‑directed therapies are being considered for colorectal cancer, PET/CT may be used as part of initial work‑up/staging — document the contrast contraindication on the request.

    Documentation Required

    Require clinical criteria documentation for suspected Richter’s transformation

    Before ordering PET/CT for suspected Richter’s transformation in CLL/SLL, ensure documentation supports B symptoms, rapidly growing lymph nodes, development of extranodal disease, or a significant recent rise in LDH — these criteria are required for medical necessity.

    Step Therapy

    Pre‑biopsy PET/CT for pulmonary masses ≥31 mm only if it will change management

    For a pulmonary mass ≥31 mm, PET/CT prior to biopsy is appropriate only when PET findings will change management (e.g., definitive resection/radiation instead of biopsy) or will guide selection of the optimal biopsy site among multiple options.

    Step Therapy

    CAR‑T peri‑treatment PET/CT: one pre‑treatment and one 30–60 days post

    For CAR‑T cell therapy, PET/CT is appropriate once before treatment and once 30–60 days after completion; authorization and scheduling should reflect these peri‑treatment timepoints.

    Step Therapy

    Step‑up to PET/CT when prior imaging inconclusive or negative PET changes management

    When a negative PET will permit management to change to maintenance or surveillance, or when conventional imaging is inconclusive, PET/CT is considered the next step; include this clinical intent in the authorization request.

    Documentation Required

    Obtain/record prior imaging results before PET/CT when applicable

    Providers should obtain or document prior imaging (CT, MRI, Octreotide, MIBG, or SPECT) before PET when those modalities are appropriate; PET is medically necessary only when those studies are negative or inconclusive.

    Documentation Required

    Document SSR PET to assess somatostatin‑analogue therapy candidacy

    For locally advanced or metastatic bronchopulmonary/thymic carcinoids not amenable to curative resection, PET with SSR radiotracers may be used to assess candidacy for somatostatin‑analogue therapy — state that treatment planning is the purpose on the authorization.

    Documentation Required

    Document therapy‑timed imaging windows for lymphoma

    Therapy‑timed imaging for lymphoma must follow the policy’s specified timing windows (e.g., treatment response and interim scans relative to chemotherapy cycles); reference the relevant cycle/timing on the request.

    Documentation Required

    Specify chemotherapy cycle timing for interim DLBCL response PET/CT

    Interim response PET/CT for DLBCL is permitted after 2–4 cycles of chemotherapy for stage II with extensive mesenteric disease and for stages III–IV; include cycle number and clinical indication on authorization.

    Denial Risk

    Do not request PET/CT when conventional studies are diagnostic

    When conventional studies (CT/MRI/bone scan) are diagnostic, requests for FDG PET/CT do not meet the policy’s medical appropriateness conditions and will not be approved; documentation must show conventional studies were non‑diagnostic.

    Documentation Required

    Document biopsy non‑diagnostic or unsafe when requesting FES PET/CT

    18F‑FES PET/CT to determine ER status is indicated only when biopsy of the metastatic site is non‑diagnostic/inconclusive or biopsy is risky/unable to be performed — include this documentation with the request.

    Documentation Required

    Provide rising CEA or abnormal LFTs with negative imaging for colorectal restaging

    For colorectal cancer restaging, provide documentation of rising postoperative carcinoembryonic antigen (CEA) or abnormal LFTs with recent negative conventional imaging to justify PET/CT.

    Documentation Required

    Document isolated metastasis and candidacy for curative local therapy

    When PET/CT is requested for metastasis‑directed restaging, document isolated metastatic lesion(s) on other imaging and that the patient is a candidate for aggressive surgical resection or other localized curative therapy.

    Documentation Required

    Provide nodule/mass size and clinical rationale for lung PET/CT

    Document pulmonary nodule size (8–30 mm) or pulmonary mass size (≥31 mm) with imaging reports and provide the clinical rationale (e.g., pre‑biopsy planning, selection of biopsy site, or intent to proceed to definitive resection/radiation) to support PET/CT necessity.

    Documentation Required

    Document limited‑stage SCLC or inconclusive imaging for PET/CT

    For initial SCLC staging, document that conventional CT chest/abdomen/pelvis and MRI brain indicate limited‑stage disease (confined to one side of the chest) or that conventional imaging is inconclusive to justify PET/CT.

    Documentation Required

    Document timing and Deauville score for Hodgkin PET/CT requests

    For Hodgkin lymphoma requests, document timing relative to prior PET/CT (>1 month), the number of chemotherapy cycles (if interim response), and end‑of‑therapy timing (e.g., at least 12 weeks after radiation) or Deauville score when seeking a 3‑month follow‑up.

    Documentation Required

    Include specific clinical indication on authorization

    Authorization requests must include the specific clinical reason for PET/CT (e.g., to identify an optimal biopsy site, suspected transformation, CAR‑T timing, Deauville 4–5 follow‑up, melanoma stage criteria, inconclusive conventional imaging, or Merkel cell recurrence) as listed in the policy.

    Documentation Required

    Document biopsy‑proven recurrence or in‑transit concern for Merkel cell PET/CT

    For Merkel cell carcinoma restaging when no prior conventional imaging exists, provide documentation of biopsy‑proven recurrence or clinical suspicion of in‑transit metastatic disease to support PET/CT.

    Documentation Required

    Provide prior imaging and pelvic exam for occult primary PET/CT

    When PET/CT is requested for an occult primary, document prior CT/MRI, bone scan, diagnostic mammogram and full pelvic exam, or CT showing isolated metastatic disease for planned definitive curative therapy.

    Documentation Required

    Document prior diagnostic PET/CT and specific reason for repeat PET/CT

    When requesting repeat whole‑body FDG PET/CT, include documentation that PET/CT was used at initial diagnosis and state the treatment‑response rationale (e.g., after completion of primary therapy, non‑secretory myeloma, inconclusive labs, or extra‑osseous plasmacytoma response).

    Documentation Required

    Include prior imaging results demonstrating negative/inconclusive studies

    Prior authorization requests should include prior imaging modality and results (CT, MRI, Octreotide, MIBG, SPECT) showing negative or inconclusive findings when FDG PET/CT or SSR PET is requested based on inconclusive prior studies.

    Documentation Required

    Support FDG PET/CT requests with documentation of negative prior studies or abnormal markers

    When FDG PET/CT is requested because other imaging or somatostatin‑receptor studies are negative, provide documentation such as persistent abnormal markers after resection or biopsy‑proven NET of unknown primary with prior negative CT/MRI and SSR study.

    Documentation Required

    Provide prior CT/MRI and SSR study results for neuroendocrine PET/CT

    Supporting imaging documentation for neuroendocrine tumor PET/CT requests must show continued suspicion after negative or inconclusive CT/MRI or somatostatin‑receptor studies, or evidence supporting PRRT candidacy assessment.

    Documentation Required

    Document clinical reason for lymphoma PET/CT (biopsy selection, CAR‑T timing, transformation)

    For lymphoma PET/CT requests, document the clinical reason (e.g., to select biopsy site, suspected transformation, CAR‑T timing) and prior relevant studies to justify medical necessity.

    Documentation Required

    Require biopsy confirmation or specified recurrence evidence for restaging PET/CT

    For diagnostic restaging PET/CT, provide biopsy confirmation of recurrence or specific suspected‑recurrence circumstances (e.g., bone involvement) as described in the policy.

    Denial Risk

    Denial risk if conventional studies are diagnostic

    Requests for PET/CT when conventional studies are diagnostic will not meet appropriateness criteria and may be denied; ensure documentation demonstrates conventional studies were non‑diagnostic.

    Denial Risk

    High denial risk for routine surveillance in asymptomatic patients

    Routine surveillance PET/CT in asymptomatic individuals with no clinical or laboratory evidence of disease (including breast cancer) is not routinely medically necessary and may be denied; indicate clinical concern or markers if applicable.

    Denial Risk

    Denial risk for colorectal surveillance and small bowel initial staging

    PET/CT requests for surveillance of colorectal cancer or initial staging of small bowel cancer are identified as not medically necessary and may be denied unless specific restaging criteria (e.g., rising CEA, isolated metastasis) are documented.

    Denial Risk

    Do not order PET/CT for small bowel initial staging or routine surveillance without qualifiers

    Ordering PET/CT for initial staging of small bowel cancer or routine surveillance in asymptomatic individuals without clinical or laboratory evidence of disease are explicit denial triggers — do not submit without qualifying documentation.

    Denial Risk

    Surveillance PET/CT requests without clinical/lab evidence face denial

    Requests for PET/CT for routine surveillance in an asymptomatic individual with no clinical or laboratory evidence of disease may be denied; include objective findings or markers to justify imaging when relevant.

    Denial Risk

    Surveillance PET/CT in asymptomatic patients not routinely covered

    Routine PET/CT surveillance in asymptomatic individuals without clinical or laboratory evidence of disease is not routinely medically necessary and may be denied — ensure the request documents an approved indication.

    Denial Risk

    Restaging PET for SCLC is usually not covered — case‑by‑case exceptions only

    PET imaging for evaluation of treatment response or recurrence of SCLC is generally not medically necessary and may be denied unless considered on a case‑by‑case basis with supporting documentation.

    Denial Risk

    Denial trigger: PET/CT prior to histologic lymphoma confirmation or routine surveillance

    PET/CT requests prior to histologic confirmation of lymphoma or routine surveillance PET/CT in asymptomatic individuals with no clinical/laboratory evidence of disease may be denied; do not submit pre‑biopsy indications without histologic support.

    Denial Risk

    Surveillance exclusion: asymptomatic patients without evidence of recurrence

    Surveillance PET/CT imaging for an asymptomatic individual with no clinical or laboratory evidence of recurrent disease is an exclusion and may be denied — document clinical rationale if imaging is requested.

    Denial Risk

    Liver PET for post‑ablation response or routine surveillance is not covered

    PET imaging of the liver is not medically necessary to assess response to ablation therapy or for routine surveillance of asymptomatic individuals after treatment completion; authorization for these reasons may be denied.

    Denial Risk

    PET/CT may be denied if low‑dose skeletal CT is available and practical

    Use of PET/CT when whole‑body low‑dose skeletal CT is available and practical may not meet medical necessity; document why CT is unavailable or impractical when requesting PET/CT for suspected recurrence/progression.

    Denial Risk

    Prior imaging must be negative/inconclusive when required — otherwise denial risk

    Requests may be denied if prior CT or MRI is not negative or inconclusive when continued suspicion is the indication; include prior imaging interpretation showing negativity or inconclusiveness with the request.

    Denial Risk

    Surveillance PET/CT without clinical evidence faces high denial risk

    PET imaging is not routinely medically necessary for surveillance imaging in asymptomatic individuals with no clinical or laboratory evidence of disease — such requests carry a high denial risk unless covered exceptions apply.

    Denial Risk

    Carcinoid surveillance PET/CT in asymptomatic patients not routinely covered

    PET/CT surveillance imaging for asymptomatic individuals with bronchopulmonary/thymic carcinoid and no clinical or laboratory evidence of disease is not routinely medically necessary and may be denied.

    Denial Risk

    Surveillance PET/CT requests without qualifying findings will be denied

    Requests for PET/CT surveillance imaging in an asymptomatic individual with no clinical or laboratory evidence of disease will be denied as not medically necessary unless a covered exception is documented.

    Denial Risk

    Routine surveillance PET/CT in asymptomatic patients is generally not covered

    PET/CT imaging is not routinely medically necessary for surveillance imaging in asymptomatic individuals without clinical or laboratory evidence of disease; such requests are at risk for denial unless specific criteria are met.

    Note
    Applies toNSCLC and SCLC pre-biopsy considerations
    inv-101: Age threshold for bone PET/CT
    Age threshold for bone PET/CT>= 40 years
    Indications at this ageBone lesion seen on x-ray or symptomatic bone lesion with suspected malignancy in individuals without prior malignancy
    Alternate indicationFDG PET/CT when bone metastases are suspected and bone scan plus CT or MRI are inconclusive
    inv-102: Lung nodule size threshold
    Lung nodule size threshold>= 8 mm
    Coverage noteLung nodules ≥8 mm meet an indication for PET/CT per policy
    ContextUsed to identify lung nodules warranting PET evaluation for staging or further work-up
    inv-103: Surveillance frequency
    Surveillance frequency for smoldering myeloma and multiple myelomaAnnual (if whole-body FDG PET/CT was the modality used at diagnosis)
    Solitary plasmacytoma surveillanceAnnual for 5 years
    ConditionSurveillance PET/CT permitted only when same modality used at diagnosis
    Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin
    inv-230: PET/CT — CAR-T schedule once before and once 30-60 days after completion
    CAR-T peri-treatment scheduleOne PET/CT before treatment and one PET/CT 30–60 days after completion
    Applies toCAR-T cell therapy monitoring for lymphoma and multiple myeloma contexts cited
    Authorization notePrior authorization should reflect planned timing for pre/post CAR‑T scans
    inv-231: PET/CT — CAR-T baseline and post-CAR-T; Deauville follow-up
    CAR-T baseline and post-CAR-TOne baseline PET/CT before CAR-T and one PET/CT 30–60 days after completion
    Deauville follow-upA single 3-month follow-up PET/CT may be approved if end-of-therapy PET shows Deauville 4–5
    Applies toHodgkin and related lymphoma surveillance around CAR-T therapy
    inv-232: FDG PET/CT — CAR-T and stem cell transplant timing
    FDG PET/CT timing for CAR-T and stem cell transplantOnce before and once 30–60 days after CAR‑T; once before and once within 30–100 days after stem cell transplant
    Applies toWhole-body FDG PET/CT peritransplant and peri‑CAR‑T imaging
    DocumentationPrior authorization should reflect planned timing for these treatment‑timed studies
    inv-233: Whole-body FDG PET/CT — Annual surveillance rules
    Annual whole-body FDG PET/CT surveillanceAnnual surveillance when same imaging modality was used at diagnosis
    Solitary plasmacytomaAnnually for 5 years
    Eligible populationsSmoldering myeloma and multiple myeloma (annual)
    Prior Authorization

    Authorize PET/CT for post‑diagnosis NSCLC or to confirm limited SCLC

    PET/CT is medically necessary for initial staging after tissue diagnosis or to confirm limited SCLC when conventional imaging indicates limited disease — include this rationale in authorization requests.

    Prior Authorization

    Document Deauville 4–5 to authorize single 3‑month follow‑up

    A single follow‑up PET/CT at 3 months may be approved for Deauville 4 or 5; ensure the end‑of‑therapy PET/CT showing Deauville 4–5 is documented on the authorization.

    Prior Authorization

    Authorize single 3‑month follow‑up (Deauville 4–5) and CAR‑T scans with timing documented

    Single follow‑up at 3 months for Deauville 4–5 and CAR‑T baseline and 30–60 day post‑treatment scans require prior authorization that documents the specific indication and timing.

    Prior Authorization

    Authorize PET/CT for Merkel cell restaging or specified adrenal evaluations

    PET/CT is required (authorization) when used for Merkel cell carcinoma restaging/recurrence or for specified adrenal metastatic evaluation as described in the policy; include the supporting clinical details.

    Prior Authorization

    Document/authorize CAR‑T related PET/CT scans

    CAR‑T related PET/CT scans (one before and one 30–60 days after completion) may require documentation/authorization — include intent and timing on the request.

    Prior Authorization

    Require FDG PET/CT for CAR‑T and stem cell transplant timing

    FDG PET/CT is required for pre/post CAR‑T and for pre/post stem cell transplant timing‑based studies (once before and once 30–60 days after CAR‑T; once before and once within 30–100 days after transplant) and should be reflected in authorization requests.

    Prior Authorization

    Authorize PET/CT/PET‑MRI for PRRT candidacy

    PET/CT (or PET/MRI) is medically necessary to assess candidacy for PRRT with Lutetium‑177 Lu‑dotatate; prior authorization should reference PRRT assessment.

    Prior Authorization

    Document SSR agent when requesting SSR PET for NETs

    Use of SSR radiotracers for initial work‑up/staging or when CT/MRI is inconclusive should be documented and prior authorization should reference the specific SSR agent requested.

    Prior Authorization

    Authorize SSR PET for PRRT candidacy or restaging with supporting documentation

    PET/CT or PET/MRI used to assess PRRT candidacy or for restaging/recurrence with SSR radiotracers requires prior authorization with documentation of continued suspicion and prior negative/inconclusive CT/MRI.

    Note
    18F‑FES (fluoroestradiol) PET/CT to determine estrogen receptor (ER) status of suspected/known metastatic breast cancer
    IndicationUse when biopsy of metastatic site is non-diagnostic or unsafe (brain, spine, vascular proximity)
    ContextUsed to evaluate ER status when conventional methods or biopsy are not feasible
    inv-170: 18F Sodium Fluoride PET/CT definition
    Definition18F Sodium Fluoride (18F‑NaF) PET/CT — bone‑specific PET/CT imaging
    IndicationAppropriate when CT, MRI, bone scan, and FDG PET/CT are inconclusive for known or suspected bone metastases
    ContextUsed in breast cancer restaging/recurrence for bone evaluation
    inv-171: Restaging/Recurrence definition
    DefinitionRestaging/Recurrence — use of PET/CT after completion of therapy to evaluate residual disease or recurrence
    Timing examplesIncludes specified post-therapy windows (e.g., cervical cancer 3–6 months; esophageal GE junction >=5 weeks post-radiation)
    PurposeAssess residual or recurrent disease and guide further management or local therapy planning
    inv-172: Restaging/Recurrence definition (alternate)
    Restaging/Recurrence definition (alternate)Use of PET/CT to evaluate for recurrent or residual disease after prior therapy, including assessment for isolated metastasis amenable to localized curative treatment
    Timing considerationsMay include therapy‑specific timing such as post-chemoradiation windows
    DocumentationRequires prior imaging to be negative/inconclusive in many indications
    inv-173: Suspected Richter's transformation definition
    DefinitionSuspected Richter's transformation — CLL/SLL scenario with new B symptoms, rapidly enlarging nodes, extranodal disease, or marked LDH rise prompting PET/CT
    UsePET/CT medically necessary when those clinical features are present
    ExceptionPET not routinely used in CLL/SLL evaluation except for this suspected transformation
    inv-174: NSCLC definition
    DefinitionNon‑Small Cell Lung Cancer (NSCLC) — includes adenocarcinoma, squamous cell, adenosquamous, and large cell tumors
    Imaging rolePET/CT medically necessary for staging, pre‑biopsy planning and restaging per size and clinical criteria
    Size thresholdsPulmonary nodule 8–30 mm; mass ≥31 mm considerations
    inv-175: Deauville score
    Deauville scoreA 5‑point FDG‑PET response assessment scale referenced in policy; Deauville 4 or 5 may trigger a 3‑month follow-up PET/CT
    Use caseEnd‑of‑therapy PET/CT showing Deauville 4–5 allows single 3‑month follow-up consideration
    Applies toHodgkin lymphoma and related subtypes
    inv-176: Deauville 4 or 5
    Deauville 4 or 5FDG avidity scoring indicating residual metabolic activity that may warrant close follow-up
    Follow-up actionSingle follow-up PET/CT at 3 months may be approved when end‑of‑therapy PET shows Deauville 4 or 5
    ContextUsed in Hodgkin and nodular lymphocyte predominant Hodgkin management
    inv-177: CAR-T cell therapy PET/CT schedule
    CAR‑T PET/CT scheduleOne PET/CT before CAR‑T therapy and one PET/CT 30–60 days after completion
    PurposeBaseline disease assessment and early post‑treatment response/candidacy evaluation
    AuthorizationPrior authorization may be required to document intent for these timing‑based scans
    inv-178: FDG PET/CT for bone
    FDG PET/CT for boneIndicated when bone metastases are suspected and bone scan plus CT or MRI are inconclusive
    Age-related indicationAlso indicated for individuals ≥40 years with bone lesion on x‑ray or symptomatic bone lesion with suspected malignancy
    Tracer18F‑FDG PET/CT referenced for bone metastatic evaluation
    inv-179: Whole-body FDG PET/CT
    Whole-body FDG PET/CTPositron emission tomography combined with CT using FDG tracer for whole‑body assessment
    UseMedically necessary for staging/restaging in multiple myeloma/plasmacytomas under listed indications
    Surveillance noteCan be used annually for specific myeloma surveillance when same modality used at diagnosis
    inv-181: PRRT definition
    PRRTPeptide receptor radionuclide therapy (assessment with PET/CT to determine candidacy for Lutetium‑177 Lu‑dotatate)
    Use casePET/CT medically necessary to assess candidacy for PRRT
    Associated tracersAssessment often performed with SSR radiotracers
    inv-182: SSR radiotracers list
    SSR radiotracers list68Ga‑DOTATATE; 68Ga‑DOTATOC; 64Cu‑DOTATATE
    UseSomatostatin‑receptor–targeted radiotracers used for PET imaging of neuroendocrine tumors and carcinoids
    IndicationsInitial work‑up/staging and restaging/recurrence when CT/MRI are negative or inconclusive